https://www.selleckchem.com/pr....oducts/avacopan-ccx1
42; 95% confidence interval [CI], 1.25-1.62; p .001), CV mortality (HR, 1.64; 95% CI, 1.32-2.05; p .001) and MACE (HR, 1.75; 95% CI, 1.38-2.22; p .001) in patients with AF. No significant relationship was found in major bleeding (HR, 1.22; 95% CI, 0.95-1.57; p=0.118), myocardial infarction (MI) (HR, 2.07; 95% CI, 1.17-3.67; p=.038), and stroke (HR, 1.14; 95% CI, 0.87-1.50, p=0.351). PAD is associated with an increased risk of all-cause mortality, CV mortality, and MACE in patients with AF. However, no significant